INCR: InterCure Ltd Forward P/S Multiple

Graphic logo of InterCure Ltd. (INCR)

InterCure Ltd. (INCR) minimizes regional risks by diversifying sales between Europe and Israel. The forward P/S valuation history demonstrates the dynamics of capitalization relative to future sales, where the 0.50 mark records this metric. High pharmacy standards and variety patents protect the business from competitors. Growth relies on exclusive contracts with European brands as part of its expansion.

INCR InterCure: Forward Price to Sales in the range 09/25/2023 - 11/13/2026

Metric breakdowns and analytics for intercure.co (INCR)

- stock price and consensus target price:
Stock Quotes InterCure|INCR - Analyst Forecast Prices
- market capitalization information:
Market Capitalization INCR|INCR - Total Enterprise Value
- issuer book value statistics:
Net Assets per Single Share InterCure|INCR - Accounting Value of Company|Market Capitalization to Book Value Ratio intercure.co|INCR - Cumulative Company Assets
- debt and liquidity data:
Total Debt to Equity Ratio InterCure Ltd.|INCR - Long-Term Debt to Capital|Short-Term Debt to Equity InterCure|INCR - Aggregate Debt Obligations|Debts to Book Capitalization INCR|INCR - Long-Term Debt|Company Current Liabilities InterCure|Quick Liquidity intercure.co
- business earnings and investment ratios data:
INCR - Company Net Income|Future Profit InterCure Ltd.|INCR - Market Price to Net Income Ratio|Forward P/E Multiple InterCure|INCR - Growth-Adjusted P/E Ratio|Enterprise Value to EBITDA Ratio INCR|INCR - Operating income before deduction of amortization|Net earnings per share (EPS TTM) InterCure|INCR - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months intercure.co|INCR - Earnings per share growth this year|Earnings growth forecast for next year InterCure Ltd.
- company sales and revenue statistics:
INCR - Company Sales|Company Projected Revenue InterCure|INCR - Market Capitalization-to-Revenue Ratio|Price-to-Projected Revenue Ratio INCR
Summary company analysis:Canndoc INCR
Manufactured products of InterCure

InterCure Ltd. (INCR) status as a leading Israeli medical cannabis operator with exclusive market access makes the company's cash flows predictable. By analyzing the forward P/S based on forecasts, an investor assesses the ratio of current market capitalization to expected revenue, which helps determine the degree of asset undervaluation or the risk of acquiring a business with declining sales during periods of market volatility.

Competitor analysis

Indivior - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio COLL (Collegium Pharma)|Cronos - Forward P/S Multiple|Market Cap to Future Revenue Ratio Canopy Growth Corp.|High Tide Inc. (HITI) - Price-to-Projected Revenue Ratio|Aurora Cannabis Inc. - Forward Price to Sales|ACHV (Achieve Life Sciences, Inc.) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Skye Bioscience Inc. (SKYE)|Forward Price-to-Revenue Multiple ANEB (Anebulo)|Forward P/S Multiple nutriband.com (NTRB)|Price-to-Projected Revenue Ratio Nasus Pharma NSRX|Forward Price to Sales IGC|MIRA Pharma - Forward P/S Multiple|Market Cap to Future Revenue Ratio Flora Growth Corp|IMCC (imcannabis.com) - Forward Price-to-Revenue Multiple|Adial Pharmaceuticals, Inc. - Forward Price to Sales|Price-to-Projected Revenue Ratio Artelo Biosciences Inc.|Price-to-Projected Revenue Ratio ENSC|Forward Price-to-Revenue Multiple TTNP (Titan Pharmaceuticals)|Price to Expected Revenue Ratio GNLN|Forward P/S Multiple INM (InMed Pharma)|AKAN: Market Cap to Projected Revenue|ENVB: Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Bright Green BGXX|HPCO: Forward P/S Multiple